Statin Lactonization by Uridine 5′-Diphospho-glucuronosyltransferases (UGTs)
- 6 October 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (11) , 4048-4055
Abstract
Statins are cholesterol-lowering drugs that have proven to be effective in lowering the risk of major cardiovascular events. Although well tolerated, statin-induced myopathies are the most common side effects. Compared to their pharmacologically active acid form, statin lactones are more potent inducers of toxicity. They can be formed by glucuronidation mediated by uridine 5′-diphospho-glucuronosyltransferases (UGTs), but a systematic characterization of subtype specificity and kinetics of lactonization is lacking. Here, we demonstrate for six clinically relevant statins that only UGT1A1, 1A3, and 2B7 contribute significantly to their lactonization. UGT1A3 appeared to have the highest lactonization capacity with marked differences in statin conversion rates: pitavastatin ≫ atorvastatin > cerivastatin > lovastatin > rosuvastatin (simvastatin not converted). Using in silico modeling we could identify a probable statin interaction region in the UGT binding pocket. Polymorphisms in these regions of UGT1A1, 1A3, and 2B7 may be a contributing factor in statin-induced myopathies, which could be used in personalization of statin therapy with improved safety.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (Ri 2087/1-1)
- Netherlands Organisation for Health Research and Development (CSBR09/013V)
This publication has 36 references indexed in Scilit:
- A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug ClassPLOS ONE, 2012
- Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational studyCurrent Medical Research and Opinion, 2012
- Pitavastatin: An overviewAtherosclerosis Supplements, 2011
- Statin myopathy: A common dilemma not reflected in clinical trialsCleveland Clinic Journal of Medicine, 2011
- Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitusDrug Design, Development and Therapy, 2011
- Pitavastatin: finding its place in therapyTherapeutic Advances in Chronic Disease, 2011
- A new bioinformatics analysis tools framework at EMBL-EBINucleic Acids Research, 2010
- Statin Induced Myopathy and Myalgia: Time Trend Analysis and Comparison of Risk Associated with Statin Class from 1991–2006PLOS ONE, 2008
- Crystal Structure of the Cofactor-Binding Domain of the Human Phase II Drug-Metabolism Enzyme UDP-Glucuronosyltransferase 2B7Journal of Molecular Biology, 2007
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006